Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Joy Ho

Showing results (31-40 of 81) with videos related to

Pageof 9
Sort By:
Transplantation and Cellular Therapy|May 11, 2026
Infections in the first 30-days after CAR-T therapy in Patients Not Receiving Fluoroquinolone ProphylaxisGemma K Reynolds, Mark R Dowling, Jose Valencia-Klug, et al.
British Journal of Haematology|July 12, 2022
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)Zoe McQuilten, Cameron Wellard, Elizabeth Moore, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 5, 2025
Real-World Comparison of Treatment Outcomes for Multiple Myeloma in Elderly Transplant Ineligible Patients Receiving First-Line VRd, Rd and VCd: Results From the Australian and New Zealand Myeloma and Related Diseases RegistrySarah Zhao, Cameron Wellard, Elizabeth M Moore, et al.
Haematologica|October 14, 2011
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1Silvia C W Ling, Edwin K K Lau, Ammira Al-Shabeeb, et al.
Internal Medicine Journal|August 5, 2025
Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma AustraliaGeorgia McCaughan, Hayley Beer, Christian Bryant, et al.
Internal Medicine Journal|December 8, 2023
Sickle cell disease in Australia: a snapshot from the Australian Haemoglobinopathy RegistryAnna Nelson, P Joy Ho, Helen Haysom, et al.
Internal Medicine Journal|January 8, 2026
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory GroupShirlene Sim, Georgia McCaughan, Andrew Zannettino, et al.
Blood|March 2, 2010
Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapyJia Li, Daniel M-Y Sze, Ross D Brown, et al.
Immunology and Cell Biology|January 22, 2016
A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subsetChristian Bryant, Phillip D Fromm, Fiona Kupresanin, et al.
Internal Medicine Journal|May 6, 2025
Economic burden of sickle cell disease in AustraliaSteve Nwokeocha, Helen E Haysom, Cameron Wellard, et al.
Pageof 9

Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Transplantation and Cellular Therapy|May 11, 2026
Infections in the first 30-days after CAR-T therapy in Patients Not Receiving Fluoroquinolone ProphylaxisGemma K Reynolds, Mark R Dowling, Jose Valencia-Klug, et al.
British Journal of Haematology|July 12, 2022
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)Zoe McQuilten, Cameron Wellard, Elizabeth Moore, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 5, 2025
Real-World Comparison of Treatment Outcomes for Multiple Myeloma in Elderly Transplant Ineligible Patients Receiving First-Line VRd, Rd and VCd: Results From the Australian and New Zealand Myeloma and Related Diseases RegistrySarah Zhao, Cameron Wellard, Elizabeth M Moore, et al.
Haematologica|October 14, 2011
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1Silvia C W Ling, Edwin K K Lau, Ammira Al-Shabeeb, et al.
Internal Medicine Journal|August 5, 2025
Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma AustraliaGeorgia McCaughan, Hayley Beer, Christian Bryant, et al.
Internal Medicine Journal|December 8, 2023
Sickle cell disease in Australia: a snapshot from the Australian Haemoglobinopathy RegistryAnna Nelson, P Joy Ho, Helen Haysom, et al.
Internal Medicine Journal|January 8, 2026
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory GroupShirlene Sim, Georgia McCaughan, Andrew Zannettino, et al.
Blood|March 2, 2010
Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapyJia Li, Daniel M-Y Sze, Ross D Brown, et al.
Immunology and Cell Biology|January 22, 2016
A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subsetChristian Bryant, Phillip D Fromm, Fiona Kupresanin, et al.
Internal Medicine Journal|May 6, 2025
Economic burden of sickle cell disease in AustraliaSteve Nwokeocha, Helen E Haysom, Cameron Wellard, et al.
Pageof 9